Cargando…

Unfractionated and low molecular weight heparin

Detalles Bibliográficos
Autores principales:	Lima, Marcelo, Nader, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204200/ http://dx.doi.org/10.1186/1753-6561-8-S4-O10

Ejemplares similares

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Inhibition of Gastric Acid Secretion by Unfractionated and Low Molecular Weight Heparins in the Rat
por: Abdel Salam, Omar M.E., et al.
Publicado: (2006)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Effect of unfractionated and low molecular weight heparin on microcirculatory antithrombin effects during endotoxemia
por: Hoffmann, JN, et al.
Publicado: (2002)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
por: Lazrak, Hind Harrak, et al.
Publicado: (2017)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: A systematic review and meta-analysis
por: Qureshi, Anjum, et al.
Publicado: (2017)

Unfractionated heparin as a safe alternative in a case of low molecular weight heparin-induced thrombocytosis: A case report
por: Jabira, Salem, et al.
Publicado: (2021)

Cartridge-Based Thromboelastography Can Be Used to Monitor and Quantify the Activity of Unfractionated and Low-Molecular-Weight Heparins
por: Dias, João D., et al.
Publicado: (2019)

Impact of nebulized unfractionated heparin and N-acetylcysteine in management of smoke inhalation injury
por: Elamin, E, et al.
Publicado: (2009)

Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
por: Ponert, Jan Moritz, et al.
Publicado: (2018)

Effect of long‐term use of unfractionated or low‐molecular‐weight heparin on bone mineral density in maintenance hemodialysis patients
por: Yang, Shuo, et al.
Publicado: (2020)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Postoperative management of antithrombotic medication in microvascular head and neck reconstruction: a comparative analysis of unfractionated and low-molecular-weight heparin
por: Sievert, Matti, et al.
Publicado: (2020)

Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis
por: Palamaner Subash Shantha, Ghanshyam, et al.
Publicado: (2015)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
por: Greiner, Jeanette, et al.
Publicado: (2019)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing
por: Schurr, James W., et al.
Publicado: (2019)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Monitoring of treatment with low molecular weight heparins using viscoelastic devices
por: Schött, U, et al.
Publicado: (2014)

Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation
por: Stokol, Tracy, et al.
Publicado: (2016)

Corrigendum to “Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention” [Indian Heart J. 68 (2) (2016) 213–224]
por: Ali-Hasan-Al-Saegh, Sadeq, et al.
Publicado: (2017)

Use of a fixed, body weight-unadjusted loading dose of unfractionated heparin for extracorporeal cardiopulmonary resuscitation
por: Iwashita, Yoshiaki, et al.
Publicado: (2015)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity
por: Li, Binghan, et al.
Publicado: (2016)

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin
por: Kalaska, Bartlomiej, et al.
Publicado: (2015)

Individual variation in unfractionated heparin dosing after pediatric cardiac surgery
por: Hikino, Keiko, et al.
Publicado: (2020)

Validation of high concentrated thrombin time assay for unfractionated heparin monitoring
por: Apipongrat, Dollapak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0llq64qvaho4bupe0inqsu639p